- Conditions
- Sickle Cell Disease
- Interventions
- ITU512, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 55 Years
- Enrollment
- 161 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2030
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Miami, Florida • Boston, Massachusetts + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1153–1176
of 3,448
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
- Interventions
- BGB-43395, Fulvestrant, Letrozole, Elacestrant, Anti-Diarrheal Agent
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 433 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 9
- States / cities
- Denver, Colorado • Lake Mary, Florida • Detroit, Michigan + 6 more
- Conditions
- Pharmacodynamic
- Interventions
- Nalmefene hydrochloride, Naloxone hydrochloride
- Drug
- Lead sponsor
- Opiant Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Non-alcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease
- Interventions
- Placebo, PF-06865571
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 6
- States / cities
- Anaheim, California • New Haven, Connecticut • South Miami, Florida + 3 more
- Conditions
- Pregnancy
- Interventions
- ciprofloxacin, azithromycin, gentamicin
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- semaxanib
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Gout
- Interventions
- SEL-110, SEL-212, SEL-037
- Drug · Biological
- Lead sponsor
- Selecta Biosciences, Inc.
- Industry
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 6
- States / cities
- Little Rock, Arkansas • Miami, Florida • Orlando, Florida + 3 more
- Conditions
- Anemia Associated With Chronic Kidney Disease
- Interventions
- Vadadustat, Darbepoetin alfa, Epoetin alfa
- Drug
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 10
- States / cities
- Escondido, California • Denver, Colorado • Fort Lauderdale, Florida + 7 more
- Conditions
- Neovascular Age-related Macular Degeneration, Retinal Disease, Retinal Degeneration, Macular Degeneration
- Interventions
- GEM103, Aflibercept, Sham
- Biological · Drug
- Lead sponsor
- Gemini Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Campbell, California • Encino, California + 19 more
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- TERN-201, Placebo
- Drug · Other
- Lead sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 11
- States / cities
- Tucson, Arizona • Coronado, California • Los Angeles, California + 5 more
- Conditions
- Non-Alcoholic Steatohepatitis
- Interventions
- SHP626, Placebo
- Drug
- Lead sponsor
- Mirum Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Advanced Solid Tumors, Neoplasms, Carcinoma, Cancer, Malignancy
- Interventions
- CVX-045
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Santa Monica, California • Philadelphia, Pennsylvania
- Conditions
- Obesity
- Interventions
- DA-1726, Placebo to DA-1726
- Drug
- Lead sponsor
- NeuroBo Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Dermatitis, Atopic
- Interventions
- BBI-5000
- Drug
- Lead sponsor
- Fresh Tracks Therapeutics, Inc.
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
- Interventions
- EDP-978, Placebo
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive MS (SPMS), Secondary Progressive Multiple Sclerosis (SPMS), Secondary Progressive MS, Non-Active SPMS, Non-Active Secondary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
- Interventions
- SUN-627, Placebo
- Drug · Other
- Lead sponsor
- Sundance Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 7
- States / cities
- Tampa, Florida • Atlanta, Georgia • Stony Brook, New York + 4 more
- Conditions
- Central Nervous System Lymphoma, Intraocular Lymphoma
- Interventions
- Intraventricular Rituximab Plus MTX
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 4
- States / cities
- San Francisco, California • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- IgA Nephropathy
- Interventions
- BION-1301 Single Dose, Placebo Single Dose, BION-1301 Multiple Doses, Placebo Multiple Doses
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2026
- U.S. locations
- 9
- States / cities
- Northridge, California • Denver, Colorado • Orlando, Florida + 6 more
- Conditions
- Cystic Fibrosis
- Interventions
- MP-376 (Levofloxacin solution for Inhalation), placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 14
- States / cities
- La Jolla, California • Los Angeles, California • Palo Alto, California + 10 more
- Conditions
- Locally Advanced / Metastatic Solid Tumors
- Interventions
- CR-001, Paclitaxel, trifluridine and tipiracil, Pemetrexed, Carboplatin, Oxaliplatin, Gemcitabin, Cisplatin, Capecitabine, FOLFOX
- Drug
- Lead sponsor
- Crescent Biopharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 12 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- InsuPatch
- Device
- Lead sponsor
- Insuline Medical Ltd.
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Nausea and Vomiting, Chemotherapy-Induced
- Interventions
- Casopitant (GW679769) oral tablets, Warfarin oral tablets
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 2
- States / cities
- Gainesville, Florida • Buffalo, New York
- Conditions
- Major Depressive Disorder
- Interventions
- LY2216684, Placebo-matching LY2216684, Placebo-matching alcoholic beverage, Alcoholic beverage
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Evansville, Indiana
- Conditions
- Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
- Interventions
- KT-474/Placebo, KT-474
- Drug
- Lead sponsor
- Kymera Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 154 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Sun City West, Arizona • Boynton Beach, Florida + 8 more